LP-168 / Lupeng Pharma |
NCT05716087: A Study of LP-168 in Participants With Relapse or Refractory Mantle Cell Lymphoma |
|
|
| Recruiting | 2 | 62 | RoW | LP-168, NWP-775 | Guangzhou Lupeng Pharmaceutical Company LTD. | Mantle Cell Lymphoma (MCL) | 02/24 | 12/25 | | |
| Completed | 1 | 70 | RoW | LP-168 tablet, NWP-775, LP-168 Placebo tablet, NWP-775 Placebo | Guangzhou Lupeng Pharmaceutical Company LTD. | Multiple Sclerosis, NMO Spectrum Disorder | 11/22 | 12/22 | | |
| Recruiting | 1 | 60 | US | LP-168 | Newave Pharmaceutical Inc | CLL/SLL, Waldenstrom Macroglobulinemia, Follicular Lymphoma, Diffuse Large B Cell Lymphoma, Mantle Cell Lymphoma, Marginal Zone Lymphoma, Hairy Cell Leukemia | 07/25 | 12/25 | | |
NCT05917964: A Food Effect Study of LP-168 Tablets in Healthy Subjects |
|
|
| Completed | 1 | 22 | RoW | LP-168 tablet, NWP-775 | Guangzhou Lupeng Pharmaceutical Company LTD. | Mantle Cell Lymphoma | 08/23 | 08/23 | | |
NCT06126861: The Mass Balance Study of LP-168 in Healthy Subjects |
|
|
| Completed | 1 | 6 | RoW | [14C]LP-168 | Guangzhou Lupeng Pharmaceutical Company LTD. | Clinical Pharmacology | 02/24 | 03/24 | | |
NCT04993690: A Study of LP-168 in Participants With Relapse or Refractory B-Cell Lymphoma |
|
|
| Recruiting | 1 | 156 | RoW | LP-168 tablet | Guangzhou Lupeng Pharmaceutical Company LTD. | B-cell Lymphoma | 12/23 | 06/24 | | |
LP-168-CN301, NCT06251180: Phase Ib Study of Rocbrutinib in Combination With R-CHOP in Patients With Newly Diagnosed B-cell Non-Hodgkin Lymphoma |
|
|
| Recruiting | 1 | 112 | RoW | Rocbrutinib, LP-168, Rituximab, MabThera; Rituximab Biosimilar HLX01; Rituximab biosimilar TQB2303; Henlius; Halpryza, Cyclophosphamide, CTX, doxorubicin, ADM; Adriamycin; DOX; Doxorubin hydrochloride, Vincristin, VCR; Vincrystine, Prednisone, delta.1-Cortisone; 1, 2-Dehydrocortisone | Guangzhou Lupeng Pharmaceutical Company LTD. | B-cell Non-Hodgkin Lymphoma | 12/24 | 12/29 | | |